Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 136,509 |
|
|||||
| News | - | ||||||
| Day High | 2.0511 | Low High |
|||||
| Day Low | 1.84 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cognition Therapeutics Inc | CGTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.14 | 7.53% | 2.00 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.86 | 1.84 | 2.0511 | 2.00 | 1.86 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 449 | 136,509 | $ 2.00 | $ 272,390 | - | 0.9001 - 3.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 255 | $ 2.00 | USD |
Cognition Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 60.83M | 30.42M | - | 0 | -25.79M | -0.85 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cognition Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CGTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.91 | 2.0511 | 1.79 | 1.86 | 101,163 | 0.09 | 4.71% |
| 1 Month | 1.87 | 2.1599 | 1.77 | 1.95 | 132,651 | 0.13 | 6.95% |
| 3 Months | 2.33 | 2.47 | 1.75 | 1.97 | 208,249 | -0.33 | -14.16% |
| 6 Months | 1.27 | 2.79 | 0.9001 | 1.81 | 211,016 | 0.73 | 57.48% |
| 1 Year | 1.76 | 3.49 | 0.9001 | 1.90 | 156,080 | 0.24 | 13.64% |
| 3 Years | 12.15 | 13.80 | 0.9001 | 3.09 | 165,986 | -10.15 | -83.54% |
| 5 Years | 12.15 | 13.80 | 0.9001 | 3.09 | 165,986 | -10.15 | -83.54% |
Cognition Therapeutics Description
| Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. |
